Shortseller Andrew Left says Jumia's post IPO stock jump is built on fraud.
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
Nvidia's biggest acquisition is in the hands of Chinese regulators at an inopportune time.
Aetna's additive effects on CVS's earnings might be front and center, but it isn't fully actualized just yet.
Short-sellers are pointing to a big risk for Tesla investors and an opportunity for traders.
Alphabet is awaiting word today on whether the U.S. Supreme Court will hear its appeal of a $9 billion copyright lawsuit filed by tech rival Oracle Corp.
Facebook isn't finding many fans for its home device.
Ad dollars keep coming in for the Zuckerberg-led social media leader.
Qualcomm's deal with Apple has removed the smartphone ceiling for the stock.
However, soft guidance from Netflix and so-so earnings from IBM are keeping positive sentiment contained.